CA2486468A1 - Ameliorations dans la technologie de l'apport - Google Patents
Ameliorations dans la technologie de l'apport Download PDFInfo
- Publication number
- CA2486468A1 CA2486468A1 CA002486468A CA2486468A CA2486468A1 CA 2486468 A1 CA2486468 A1 CA 2486468A1 CA 002486468 A CA002486468 A CA 002486468A CA 2486468 A CA2486468 A CA 2486468A CA 2486468 A1 CA2486468 A1 CA 2486468A1
- Authority
- CA
- Canada
- Prior art keywords
- active agent
- agent
- carrier material
- dispersion
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013543 active substance Substances 0.000 claims abstract description 81
- 239000012876 carrier material Substances 0.000 claims abstract description 63
- 239000000463 material Substances 0.000 claims abstract description 50
- 239000006185 dispersion Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 210000005075 mammary gland Anatomy 0.000 claims abstract description 15
- 230000003232 mucoadhesive effect Effects 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 241000282817 Bovidae Species 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 229940124326 anaesthetic agent Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 229940125687 antiparasitic agent Drugs 0.000 claims description 2
- 239000000164 antipsychotic agent Substances 0.000 claims description 2
- 229940124575 antispasmodic agent Drugs 0.000 claims description 2
- 239000003699 antiulcer agent Substances 0.000 claims description 2
- 230000003182 bronchodilatating effect Effects 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 2
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000002138 osteoinductive effect Effects 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229920001169 thermoplastic Polymers 0.000 claims description 2
- 239000004416 thermosoftening plastic Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 239000003576 central nervous system agent Substances 0.000 claims 1
- 229940125693 central nervous system agent Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 239000000829 suppository Substances 0.000 abstract description 6
- 238000001802 infusion Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- -1 infusions Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
La présente invention concerne un dispositif destiné à être administré dans la cavité de la glande mammaire d'un sujet, comprenant au moins une substance active et au moins un excipient. Ce dispositif se caractérise en ce que l'environnement dans lequel ce dispositif est introduit active la dispersion de la substance active. Dans d'autres modes de réalisation de l'invention, un matériau muco-adhésif est utilisé comme matériau de rétention du mélange excipient/substance active. Le but de ce dispositif est d'apporter une ou des substances actives à un sujet sous la forme d'un suppositoire qui, lors de l'administration au sujet, se disperse dans l'environnement de ce sujet. Ce dispositif convient particulièrement pour apporter une substance active à la glande mammaire d'une vache en lactation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ519112A NZ519112A (en) | 2002-05-22 | 2002-05-22 | Drug delivery device for administration of active agent to mammary gland cavity |
| NZ519112 | 2002-05-22 | ||
| PCT/NZ2003/000099 WO2003097109A1 (fr) | 2002-05-22 | 2003-05-22 | Ameliorations dans la technologie de l'apport |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2486468A1 true CA2486468A1 (fr) | 2003-11-27 |
Family
ID=29546535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002486468A Abandoned CA2486468A1 (fr) | 2002-05-22 | 2003-05-22 | Ameliorations dans la technologie de l'apport |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1551330A1 (fr) |
| JP (1) | JP2005535591A (fr) |
| AU (1) | AU2003228177A1 (fr) |
| CA (1) | CA2486468A1 (fr) |
| NZ (1) | NZ519112A (fr) |
| WO (1) | WO2003097109A1 (fr) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1899492A (en) * | 1929-10-24 | 1933-02-28 | Ward L Beebe | Teat dilator |
| US2244027A (en) * | 1938-10-31 | 1941-06-03 | Benjamin D Smith | Teat dilator |
| US2704076A (en) * | 1953-02-20 | 1955-03-15 | Herbert J Larson | Dilators |
| US2832343A (en) * | 1955-04-12 | 1958-04-29 | Mose Clara Emilie Marie | Dilators |
| FR2247204A1 (en) * | 1973-10-16 | 1975-05-09 | Girardiere Gf | Veterinary aerosol foams - contg alginic acid derivs as film-formers for injection into cows teats, vagina or uterus |
| CA1052697A (fr) * | 1974-03-29 | 1979-04-17 | Upjohn Company (The) | Compose therapeutique contre la mastite chez les mammiferes |
| US3938517A (en) * | 1975-03-14 | 1976-02-17 | Anderson Carsten D | Teat cautery bullet |
| US4011312A (en) * | 1975-06-25 | 1977-03-08 | American Home Products Corporation | Prolonged release drug form for the treatment of bovine mastitis |
| GB8417810D0 (en) * | 1984-07-12 | 1984-08-15 | Graham N B | Temperature/fluid sensitive devices |
| US5116619A (en) * | 1988-08-30 | 1992-05-26 | Lee Roy Morgan | Vaginal progesterone tablet |
| NZ258199A (en) * | 1992-12-08 | 1997-01-29 | Bimeda Research & Dev Ltd | Veterinary composition for treating mastitis comprising an aqueous suspension of an insoluble salt of cloxacillin benzathine |
| IT1283324B1 (it) * | 1996-04-02 | 1998-04-16 | Fatro Spa | Composizioni veterinarie a base di antibatterici per uso intramammario |
| US6572874B1 (en) * | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
| NZ330596A (en) * | 1998-06-05 | 2001-02-23 | Dec Res | Intravaginal devices allowing for increased uptake of active ingredients |
-
2002
- 2002-05-22 NZ NZ519112A patent/NZ519112A/xx not_active IP Right Cessation
-
2003
- 2003-05-22 WO PCT/NZ2003/000099 patent/WO2003097109A1/fr not_active Ceased
- 2003-05-22 JP JP2004505104A patent/JP2005535591A/ja active Pending
- 2003-05-22 CA CA002486468A patent/CA2486468A1/fr not_active Abandoned
- 2003-05-22 AU AU2003228177A patent/AU2003228177A1/en not_active Abandoned
- 2003-05-22 EP EP03725921A patent/EP1551330A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003228177A1 (en) | 2003-12-02 |
| NZ519112A (en) | 2004-12-24 |
| WO2003097109A1 (fr) | 2003-11-27 |
| JP2005535591A (ja) | 2005-11-24 |
| EP1551330A4 (fr) | 2005-07-13 |
| EP1551330A1 (fr) | 2005-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU783538B2 (en) | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration | |
| JP3313113B2 (ja) | 雌馬の排卵制御用生体適合性インプラント | |
| AU642704B2 (en) | Long-term delivery device including loading dose | |
| US9623222B2 (en) | Drug depot with anchor | |
| US5874098A (en) | Pellet implant system | |
| EA005778B1 (ru) | Дозированная форма, устройство и способы лечения | |
| AU763614B2 (en) | Pellet implant system for immediate and delayed release of antiparasitic drug | |
| AU653425B2 (en) | Long-term delivery device including hydrophobic loading dose | |
| US20010041697A1 (en) | Implant composition containing melengestrol acetate and trenbolone acetate | |
| US20050153841A1 (en) | Injection formulation | |
| Trostle et al. | Use of antimicrobial-impregnated polymethyl methacrylate beads for treatment of chronic, refractory septic arthritis and osteomyelitis of the digit in a bull | |
| US20050152939A1 (en) | Delivery technology | |
| CA2486468A1 (fr) | Ameliorations dans la technologie de l'apport | |
| EP1549291A1 (fr) | Formulation d'injection | |
| US20040022832A1 (en) | Pain relief implant pellet and method using same | |
| AU775037B2 (en) | Pellet implant system | |
| US20090292013A1 (en) | In-Situ Forming Implant for Animals | |
| TH48412A3 (th) | องค์ประกอบสารกระตุ้นการเจริญเติบโต ที่ได้รับการปรับปรุง | |
| AU3176999A (en) | Sustained release formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |